Australia’s health 2008. Canberra: Australian Institute of Health and Welfare; 2008. Cat. No. AUS 99.
Dixon T. Costs of diabetes in Australia, 2000–01. Canberra: Australian Institute of Health and Welfare; 2005. Bulletin No. 26, AIHW Cat. No. AUS 59.
Mathers C, Vos T, Stevenson S. The burden of disease and injury in Australia. Canberra: Australian Institute of Health and Welfare; 1999. AIHW Cat. No. PHE 17.
Barr ELM, Zimmet PZ, Polkinghorne KR, Atkins RC, Dunstan CW, Murray SG, et al
. AusDiab 2005: the Australian diabetes, obesity and lifestyle study. Tracking the accelerating epidemic: its causes and outcomes. International Diabetes Institute; 2006.
Begg SJ, Vos T, Barker B, Stanley L, Lopez AD.
Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust
; 188: 36–40.
Georgiou A, Burns J, Harris M.
GP claims for completing diabetes ‘cycle of care’. Aust Fam Physician
; 33: 755–7.
Improving care. Hospital Admission Risk Program: Public Report. Melbourne: Victorian Government Department of Human Services; 2006.
Rasekaba TM. Chronic disease services patients in the Northern Alliance Hospital admission risk program-chronic disease management (HARP-CDM). 2009. MPH by Research Thesis, The University of Melbourne, Melbourne.
Craver GA, Longo DR.
Using instrumental variables regression to evaluate Medicaid disease management program effectiveness: an exploratory analysis. J Health Care Finance
; 36: 15–30.
Can a disease self-management program reduce health care costs? The case of older women with heart disease. Med Care
; 41: 706–15.
Lorig KL, Ritter P, Stewart AL, Sobel DS, Brown WB, Bandura A, Gonzalez VM, Laurent DD, Holman HR.
Chronic disease self-management program: 2-year health status and health care utilization outcomes. Med Care
; 39: 1217–23.
Strategies to control costs and quality: a focus on outcomes research for disease management. Med Care
; 42: 24–30.
Casemix Funding in Victoria. Melbourne: State Government of Victoria, Department of Health; 2009. Available at http://www.health.vic.gov.au/casemix/definitions
[verified 7 December 2009].
Australian Refined Diagnosis Related Groups (AR-DRGs). Australian Government, Department of Health and Ageing; 2009. Available at http://www.health.gov.au/internet/main/Publishing.nsf/Content/health-casemix-ardrg1.htm
[verified 8 December 2009].
International Classification of Diseases (ICD), 10th Revision 2007 (ICD-10). Geneva: World Health Organization; 2007. Available at http://www.who.int/classifications/icd/en/
[verified 8 December 2009].
Rasekaba TM, Graco M, Risteski C, Jasper A, Berlowitz DJ, Hawthorne G, Hutchinson A.
Impact of a diabetes disease management program on diabetes control and patient quality of life. Popul Health Manag
; 15: 12–9.
Clarke P, Leal J, Kelman C, Smith M, Colagiuri S.
Estimating the cost of complications of diabetes in australia using administrative health-care data. Value Health
; 11: 199–206.
Driver VR, Fabbi M, Lavery LA, Gibbons G.
The costs of diabetic foot: the economic case for the limb salvage team. J Vasc Surg
; 52: 17S–22S.
Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C,
Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study group. BMJ
; 320: 1373–8.
Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C,
Cost effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia
; 44: 298–304.
Edmonds ME, Blundell MP, Morris ME, Thomas EM, Cotton LT, Watkins PJ.
Improved survival of the diabetic foot: the role of a specialized foot clinic. Q J Med
; 60: 763–71.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA,
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ
; 321: 405–12.
ten Brinke R, Dekker N, de Groot M, Ikkersheim D.
Lowering HbA1c in type 2 diabetics results in reduced risk of coronary heart disease and all-cause mortality. Prim Care Diabetes
; 2: 45–9.
Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A,
Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ
; 322: 15–8.
Huang ES, Zhang Q, Gandra N, Chin MH, Meltzer DO.
The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med
; 149: 11–9.
The Diabetes Control and Complications Trial Research Group
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med
; 329: 977–86.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA.
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med
; 359: 1577–89.
The Action to Control Cardiovascular Risk in Diabetes Study Group
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med
; 358: 2545–59.
Casemix Calculator 2009–2010. Melbourne: Metropolitan and Aged Care Services, Department of Health (Victoria); 2009.
Evans RG. Incomplete vertical integration: the distinctive structure of the healthcare industry. In: Van Der Gaag J, Pelmon M, editors. Health economics and health economics. Amsterdam: North Holland; 1981: 329–54.
Eckermann S. Measuring health system efficiency and funding for net benefit maximisation: the health economics of quality of care. Working paper No. 2009/08. Centre for Clinical Change and Health Care Research, Finders University; 2009. Available at http://www.pc.gov.au/__data/assets/pdf_file/0011/90569/sub010-attachment1.pdf
[verified 22 December 2011].
A primer: health care databases, diagnostic coding, severity adjustment systems and improved parameter estimation. Ann Oper Res
; 67: 23–44.